177Lu-JH040182

N/A

Report date: 2026/01/15 16:13:52

NME

Base Information

Drug Name177Lu-JH040182

Drug Alias Name镥[177Lu]JH040182177Lu-JH040182177LuJH040182[177Lu]-JH04

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC) +[4]

Mechanisms of ActionFibroblast activation protein alpha binders

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesBivision Biomedical Technology (Shanghai) Co Ltd

China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBivision Biomedical Technology (Shanghai) Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A